Study of Efficacy and Safety of Rasburicase for the Treatment/Prevention of Hyperuricemia Related to Tumor Lysis Syndrome in Adult Patients With Relapsing Aggressive Non Hodgkin's Lymphoma, Previously Treated or Not With Urate Oxidase Presenting With Hyperuricemia and/or Bulky Disease
Interventional
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Masking: Open Label, Primary Purpose: Treatment
responder rate (based on normalization of uric acid levels)
ICD
Study Director
Sanofi
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
EFC4983
NCT00664144
July 2002
January 2005
Name | Location |
---|